19:17 , Sep 15, 2017 |  BC Week In Review  |  Company News

Gene therapy company Rocket finds public path

Ophthalmic play Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) will merge with gene therapy company Rocket Pharmaceuticals Ltd. (New York, N.Y.). The combined company will retain Rocket's name and will be located in New York. The partners expect...
23:26 , Sep 12, 2017 |  BC Extra  |  Company News

Gene therapy company Rocket finds public path

Ophthalmic play Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) will merge with gene therapy company Rocket Pharmaceuticals Ltd. (New York, N.Y.). The combined company will retain Rocket's name and will be located in New York. The partners expect...
14:13 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Cell culture and mouse studies identified adenosine-based dual-acting ADORA1 agonists/ ADORA3 antagonists that could help treat pain. Chemical synthesis and testing of adenosine analogs in cell-based receptor binding and activity assays yielded three...
21:34 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

Trabodenoson: Ph III MATrX-1 data

Top-line data from the double-blind, U.S. Phase III MATrX-1 trial in 303 patients with primary open-angle glaucoma or ocular hypertension showed that once-daily 3% and 6% and twice-daily 4.5% topical trabodenoson for 3 months all...
23:46 , Jan 3, 2017 |  BC Extra  |  Clinical News

Inotek plummets on Phase III glaucoma miss

Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) sank $4.35 (71%) to $1.75 after it said trabodenoson ( INO-8875 ) monotherapy missed the primary endpoint of the Phase III MATrX-1 trial to treat primary open-angle glaucoma or ocular hypertension....
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Trabodenoson: Completed Phase III enrollment

Inotek completed enrollment of about 335 patients in the double-blind, U.S. Phase III MATrX-1 trial comparing topical trabodenoson vs. twice-daily placebo or 0.5% timolol in both eyes for 12 weeks. Patients will receive 3% or...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Trabodenoson/latanoprost: Phase II started

Inotek began a double-blind, placebo-controlled, U.S. Phase II trial to compare once-daily trabodenoson/latanoprost given as a single eye drop in both eyes for 8 weeks vs. 0.0025% or 0.005% topical latanoprost in about 165 patients...
07:00 , Apr 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Adenosine A1 receptor (ADORA1)

Other INDICATION: Hearing loss Cell culture and rat studies suggest ADORA1 agonists could help treat cisplatin-induced hearing loss. In a cisplatin-treated mouse cochlear hair cell line, pretreatment with an ADORA1 agonist tool compound decreased cisplatin-induced...
07:00 , Mar 31, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Adenosine A1 receptor (ADORA1)

Cardiovascular disease INDICATION: Pulmonary Mouse studies suggest an ADORA1 antagonist conjugated to gold nanoparticles could help treat respiratory paralysis in spinal cord injury (SCI) patients with less toxicity than the free antagonist. The conjugate consisted...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

Trabodenoson: Phase III start

Inotek began the double-blind, U.S. Phase III MATRx-1 trial to compare topical trabodenoson vs. twice-daily placebo or 0.5% timolol for 12 weeks in both eyes in about 335 patients with an IOP of 24-34 mmHg....